Kodiak Sciences completes enrolment in first pivotal cohort in the phase 3 trial of KSI-101 for macular oedema secondary to inflammation and reaffirms topline clinical data release remains on track for December 2026

Kodiak Sciences Inc. has completed enrolment of the first 300-patient cohort in its clinical trial, supporting pivotal analysis of the KSI-101 phase 3 programme in macular oedema secondary to inflammation (MESI).

Kodiak also reaffirmed its plan to release the topline data from pivotal analysis 1 in December 2026.